Format

Send to

Choose Destination
See comment in PubMed Commons below
Endocrinol Metab Clin North Am. 2014 Dec;43(4):913-47. doi: 10.1016/j.ecl.2014.08.001.

Beginning to understand high-density lipoproteins.

Author information

1
Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, One Gustave Levy Place, Box 1030, New York, NY 10029, USA.
2
Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, One Gustave Levy Place, Box 1030, New York, NY 10029, USA. Electronic address: robert.rosenson@mssm.edu.

Abstract

This article reconciles the classic view of high-density lipoproteins (HDL) associated with low risk for cardiovascular disease (CVD) with recent data (genetics studies and randomized clinical trials) casting doubt over the widely accepted beneficial role of HDL regarding CVD risk. Although HDL cholesterol has been used as a surrogate measure to investigate HDL function, the cholesterol content in HDL particles is not an indicator of the atheroprotective properties of HDL. Thus, more precise measures of HDL metabolism are needed to reflect and account for the beneficial effects of HDL particles. Current and emerging therapies targeting HDL are discussed.

KEYWORDS:

Apolipoprotein A-I; Atherosclerosis; Cholesteryl ester transfer protein inhibitor; Fibrates; High-density lipoprotein; High-density lipoprotein particles; Niacin; Reverse cholesterol transport

PMID:
25432389
DOI:
10.1016/j.ecl.2014.08.001
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center